These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 25530098

  • 1. Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.
    Wada N, Kawano Y, Fujiwara S, Kikukawa Y, Okuno Y, Tasaki M, Ueda M, Ando Y, Yoshinaga K, Ri M, Iida S, Nakashima T, Shiotsu Y, Mitsuya H, Hata H.
    Int J Oncol; 2015 Mar; 46(3):963-72. PubMed ID: 25530098
    [Abstract] [Full Text] [Related]

  • 2. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M, Tabayashi T, Kimura Y, Tomikawa T, Nemoto-Anan T, Watanabe R, Tokuhira M, Ri M, Hashimoto Y, Iida S, Kizaki M.
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [Abstract] [Full Text] [Related]

  • 3. The molecular mechanisms and gene expression profiling for shikonin-induced apoptotic and necroptotic cell death in U937 cells.
    Piao JL, Cui ZG, Furusawa Y, Ahmed K, Rehman MU, Tabuchi Y, Kadowaki M, Kondo T.
    Chem Biol Interact; 2013 Sep 25; 205(2):119-27. PubMed ID: 23811387
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
    Ju D, Xie Y.
    Mol Med Rep; 2014 Nov 25; 10(5):2609-12. PubMed ID: 25174315
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
    Tagoug I, Jordheim LP, Herveau S, Matera EL, Huber AL, Chettab K, Manié S, Dumontet C.
    Clin Cancer Res; 2013 Jul 01; 19(13):3556-66. PubMed ID: 23674497
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
    Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Shiotsu Y, Ueda R.
    Leukemia; 2010 Aug 01; 24(8):1506-12. PubMed ID: 20555361
    [Abstract] [Full Text] [Related]

  • 11. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.
    Gu H, Chen X, Gao G, Dong H.
    Mol Cancer Ther; 2008 Aug 01; 7(8):2298-307. PubMed ID: 18723477
    [Abstract] [Full Text] [Related]

  • 12. Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis.
    Han W, Xie J, Li L, Liu Z, Hu X.
    Apoptosis; 2009 May 01; 14(5):674-86. PubMed ID: 19288276
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
    Ling SC, Lau EK, Al-Shabeeb A, Nikolic A, Catalano A, Iland H, Horvath N, Ho PJ, Harrison S, Fleming S, Joshua DE, Allen JD.
    Haematologica; 2012 Jan 01; 97(1):64-72. PubMed ID: 21993678
    [Abstract] [Full Text] [Related]

  • 15. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 16. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
    Zhang L, Ma YP, Jia G.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov 21; 33(11):926-31. PubMed ID: 23363750
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, Mitsiades N, Richardson P, Chang Y, Schindler J, Carver B, Anderson KC.
    Cancer Res; 2005 Sep 15; 65(18):8350-8. PubMed ID: 16166312
    [Abstract] [Full Text] [Related]

  • 19. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
    Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink PP, de Bruin G, Kisselev AF, Overkleeft H, Driessen C.
    Cancer Chemother Pharmacol; 2015 Aug 15; 76(2):383-96. PubMed ID: 26099967
    [Abstract] [Full Text] [Related]

  • 20. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
    Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ.
    Blood; 2007 Nov 01; 110(9):3281-90. PubMed ID: 17591945
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.